Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol

<p><strong>Objective:</strong> PCSK9 inhibitors have been shown to reduce LDLc by up to about 60% and 85% when used with high doses of statins and ezetimibe (2019 ESC/EAS Guidelines). These therapies may lead to very low levels of LDLc and have been associated with possible cognitive deteriora...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	José Seijas-Amigo, Diego Rodríguez-Penas, Ana Estany-Gestal, Pedro Suárez-Artime, María Santamaría-Cadavid, José Ramón González-Juanatey
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2021-05-01
Cyfres:	Farmacia Hospitalaria
Pynciau:	alirocumab evolocumab pcsk9 inhibitors cholesterol cognition lipid-lowering therapies
Mynediad Ar-lein:	http://www.aulamedica.es/fh/pdf/11569.pdf
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!